Pricing & Access· May 29, 2026 · 10 min readTecentriq and Tecentriq Hybreza bladder cancer MRD access guide: the first ctDNA-guided adjuvant immunotherapy, companion diagnostic, coding, and payer coverageOn May 15, 2026, the FDA approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as the first...By Ran Chen#Oncology#PD-L1#Companion Diagnostic
